Filter by: patients
Home > Community Treatment Reports and Side Effects > Asthmanex Treatment Report
What is Asthmanex?

Asthmanex is a brand name for the drug mometasone furoate, a corticosteroid used in the treatment of asthma. Asthmanex is a brand name owned by Schering.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Asthma 4 2 Efficacy_major Efficacy_cant_tell
Difficulty breathing at night 1 0
Bronchospasm 1 1 Efficacy_slight

See all 3 patients currently taking Asthmanex

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 3

Reported Dosages

  4 mcg daily 220 mcg daily
  1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Asthmanex (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 2   Did not seem to work: 67%
Doctor's advice 1   Doctor's advice: 33%

See all 3 patients who’ve stopped taking Asthmanex

Reported Duration See details about how long patients take this treatment ▼

Stopped Taking Asthmanex

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Asthmanex

Always
 1 33%
Usually
 1 33%
Sometimes
 1 33%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Asthmanex

Very
 0 0%
Somewhat
 0 0%
A little
 1 33%
Not at all
 2 67%

Cost

Paid out of pocket

Cost of Asthmanex

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on May 27, 2012.